

**AMENDMENT TO THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application:

1-75. (Canceled)

76. (Currently amended)     ~~The A~~ recombinant recognition molecule comprising variable heavy (VH) and variable light (VL) antibody framework sequences and complementarity determining regions (CDRs) comprising the amino acid sequences set forth in

- (i) the amino acid sequence SEQ ID NO. 1,
- (ii) the amino acid sequences SEQ ID NO.2 or 3,
- (iii) the amino acid sequence SEQ ID NO.4, 5 or 6,
- (iv) the amino acid sequence SEQ ID NO.7 or 8 or 9,
- (v) the amino acid sequence SEQ ID NO. 10 or 11, and
- (vi) the amino acid sequence SEQ ID NO. 12 or 13,

~~according to claim 74~~ wherein the antibody framework sequences

a) FRH1, FRH2, FRH3 and FRH4 for the variable heavy chain VH are the following amino acid sequences, the amino acid position corresponding to the numbering according to Kabat:

for FRH1 in position	1	Q or E
	2	V
	3	Q, K or T
	4	L

5 K or V  
6 E or Q  
7 S  
8 G  
9 A  
10 E  
11 L or V  
12 V or K  
13 R or K  
14 P  
15 G  
16 T or A  
17 S  
18 V  
19 K  
20 I or V  
21 S or P  
22 C  
23 K  
24 A, V, S or T  
25 S  
26 G  
27 Y, F, S or D  
28 T

	29	F, L or I
	30	T
for FRH2 in position	36	W
	37	V
	38	K or R
	39	Q
	40	R or A
	41	P
	42	G
	43	H or Q
	44	G
	45	L
	46	E
	47	W or R
	48	I or M
	49	G
for FRH3 in position	66	K or R
	67	A or V
	68	T
	69	L or M
	70	T
	71	A, L or T
	72	D
	73	T

74	S
75	S or T
76	S
77	T
78	A
79	Y
80	M
81	Q or E
82	L
82a	S
82b	S or R
82c	L
83	T or R
84	S
85	E
86	D
87	S or T
88	A
89	V
90	Y
91	F or Y
92	C
93	A
94	Y, K or R

for FRH4 in position	103	W
	104	G
	105	Q
	106	G
	107	T
	108	T, S or L
	109	V or L
	110	T
	111	V
	112	S
	113	S or A

b) FRL 1, FRL2, FRL3 and FRL4 for the variable light chain VT, are the following amino acid sequences, the amino acid position corresponding to the numbering according to Kabat:

for FRL 1 in position	1	D
	2	I, V or L
	3	Q or L
	4	M
	5	T
	6	Q
	7	T or S
	8	P
	9	L

10	S
11	L
12	P
13	V
14	S or T
15	L or P
16	G
17	D or E
18	Q or P
19	A
20	S
21	I
22	S
23	C
for FRL2 in position	35 W
	36 Y
	37 L
	38 Q
	39 K
	40 P
	41 G
	42 Q
	43 S
	44 P

	45	K or Q
	46	L
	47	L
	48	I or V
	49	Y
for FRL3 in position	57	G
	58	V
	59	P
	60	D
	61	R
	62	F
	63	S
	64	G
	65	S
	66	G
	67	S
	68	G
	69	T
	70	D
	71	F
	72	T
	73	L
	74	K
	75	I

76	S
77	R
78	V
79	E
80	A
81	E
82	D
83	L or V
84	G
85	V
86	Y
87	Y
88	C
for FRL4 in position	98 F
	99 G
	100 G or Q
	101 G
	102 T
	103 K
	104 L
	105 E
	106 I or L
	106a K
	107 R



108 A

and which specifically binds to the core 1 antigen.

77. (Canceled)

78. (Canceled)

79. (Previously presented) A construct comprising the recombinant recognition molecules according to claim [[74]] 76, further comprising (i) immunoglobulin domains of various species, (ii) enzyme molecules, (iii) inter-action. domains, (iv) domains for stabilization, (v) signal sequences, (vi) fluorescent dyes, (vii) toxins, (viii) catalytic antibodies, (ix) one or more antibodies or antibody fragments with different specificity, (x) cytolytic components, (xi) immunomodulators, (xii) immunoeffectors, (xiii) MHC class I or class II antigens, (xiv) chelating agents for radioactive labeling, (xv) radioisotopes, (xvi) liposomes, (xvii) transmembrane domains, (xviii) viruses and/or (xix) cells.

80. (Canceled).

81. (Previously presented) A method for the prophylaxis, diagnosis, reduction, therapy, follow-up or aftercare of a core-1 positive tumor disease or a core-1 positive metastasis, comprising administering to a subject in need thereof, a recognition molecule comprising variable heavy (VH) and variable light (VL) antibody framework sequences and complementarity determining

regions (CDRs) comprising the amino acid sequences set forth in

- (i) the amino acid sequence SEQ ID NO. 1,
- (ii) the amino acid sequences SEQ ID NO.2 or 3,
- (iii) the amino acid sequence SEQ ID NO.4, 5 or 6,
- (iv) the amino acid sequence SEQ ID NO.7 or 8 or 9,
- (v) the amino acid sequence SEQ ID NO. 10 or 11, and
- (vi) the amino acid sequence SEQ ID NO. 12 or 13,

and which specifically binds to the core 1 antigen.

82. (Previously presented) The method according to claim 81, wherein the recognition molecule is a non-labeled recognition molecule, which is an IgM or IgG or is a molecule derived therefrom.

83. (Previously presented) The method according to claim 81, wherein the recognition molecules are multibody.

84. (Previously presented) A method for the prophylaxis, diagnosis, reduction, therapy, follow-up or aftercare of a core-1 positive tumor disease or a core-1 positive metastasis, comprising administering to a subject in need thereof, a construct according to claim 79.